SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

SAN

97.37

-3.23%↓

EI

247.1

-0.68%↓

SHL.DE

46.2

-3.41%↓

ARGX

524.6

-3.78%↓

FRE

39.09

-1.71%↓

Search

Genfit

Geschlossen

BrancheGesundheitswesen

3.185 -2.3

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.16

Max

3.29

Schlüsselkennzahlen

By Trading Economics

Einkommen

30M

Verkäufe

61M

KGV

Branchendurchschnitt

8.905

63.778

Gewinnspanne

49.607

Angestellte

169

EBITDA

32M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+165.12% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

24. Apr. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

168M

Vorheriger Eröffnungskurs

5.49

Vorheriger Schlusskurs

3.185

Nachrichtenstimmung

By Acuity

100%

0%

374 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Genfit Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Apr. 2025, 23:04 UTC

Top News

JPMorgan Raises Risk of U.S., Global Recession to 60%

3. Apr. 2025, 22:40 UTC

Wichtige Markttreiber

Aldeyra Shares Fall on FDA Complete Response Letter for Dry Eye Disease Drug

3. Apr. 2025, 22:18 UTC

Akquisitionen, Fusionen, Übernahmen

Quantum Corp. Gets Strategic Investment, Names New Financial Chief

3. Apr. 2025, 18:51 UTC

Akquisitionen, Fusionen, Übernahmen

Capital One, Discover Merger Clears Regulatory Hurdle, Sources Tell The New York Times

3. Apr. 2025, 23:43 UTC

Market Talk

Gold Steady, Supported by Potential Safe-Haven Demand -- Market Talk

3. Apr. 2025, 23:41 UTC

Market Talk

Nikkei May Fall as U.S. Tariffs Raise Concerns About Global Growth -- Market Talk

3. Apr. 2025, 22:22 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 22:21 UTC

Akquisitionen, Fusionen, Übernahmen

Is TikTok Getting Banned? What to Expect as the Deadline Approaches. -- Barrons.com

3. Apr. 2025, 21:43 UTC

Top News
Ergebnisse

The Day Trump's Tariffs Shook Wall Street and Corporate America -- 5th Update

3. Apr. 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

3. Apr. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3. Apr. 2025, 20:43 UTC

Market Talk

Plummeting Toronto Home Sales Reflect Trade, Political Uncertainty -- Market Talk

3. Apr. 2025, 20:34 UTC

Top News

Trump's Tariffs Were Supposed to Boost the Dollar, But Here's Why the Opposite Happened -- Heard on the Street -- 2nd Update

3. Apr. 2025, 20:23 UTC

Top News

Trump Tariffs Send Dow Industrials to 1600-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Blackstone Life Sciences And Anthos Therapeutics Announce Novartis Has Completed The Acquisition Of Anthos Therapeutics In A Deal Valued At Up To $3.1B, With $925M Paid Upfront >BX

3. Apr. 2025, 19:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3. Apr. 2025, 19:55 UTC

Market Talk

Dollar Weakens as Investors Seek Safety Elsewhere -- Market Talk

3. Apr. 2025, 19:21 UTC

Market Talk

Oil Futures Slide on U.S. Tariffs, OPEC+ Output Plan -- Market Talk

3. Apr. 2025, 19:15 UTC

Market Talk

U.S. Natural Gas Stays Focused on Weather, Storage -- Market Talk

3. Apr. 2025, 18:45 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:45 UTC

Market Talk

Gold Drops In Tariff Fallout -- Market Talk

3. Apr. 2025, 18:39 UTC

Market Talk

U.S. Tariffs Could Give Natural Gas Edge Over Solar -- Market Talk

3. Apr. 2025, 18:38 UTC

Top News

Trump Tariffs Send Dow Industrials to 1400-Point Decline; Dollar Slumps -- WSJ

3. Apr. 2025, 18:30 UTC

Top News

Auto Industry Braces for Major Pain From Trump's Tariffs -- Analysis

3. Apr. 2025, 18:20 UTC

Market Talk

Uncertainty Still Roils Companies in Tariff Saga -- Market Talk

3. Apr. 2025, 18:18 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

3. Apr. 2025, 18:17 UTC

Market Talk

U.S. Workers Can't Match International Labor as Companies Consider Moving Supply Chains -- Market Talk

3. Apr. 2025, 18:04 UTC

Market Talk

US Sees More Job Openings in Construction, Transportation -- Market Talk

3. Apr. 2025, 17:55 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Genfit Prognose

Kursziel

By TipRanks

165.12% Vorteil

12-Monats-Prognose

Durchschnitt 8.696 EUR  165.12%

Hoch 9 EUR

Tief 8.4 EUR

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Genfit – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

2

Buy

0

Halten

0

Sell

Technischer Score

By Trading Central

3.275 / 3.315Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Strong Bearish Evidence

Stimmung

By Acuity

374 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bärische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Genfit

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.